SFX by Ex Libris Inc.

Title:	Combination of Ofatumumab and Lenalidomide in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): Results of a Phase II Trial
Source:	Blood [0006-4971] Ferrajoli, Alessandra yr:2012

Basic

Sorry, no full text available...

Please use the document delivery service (see below)

Holding information

Holdings in library search engine ALBERT

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	van der Jagt, R.. "A Canadian perspective on bendamustine for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma." Current oncology 19.3 (2012): 160-168.
description	2.	Salles, G. "Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients." Blood 119.22 (2012): 5126-5132.
description	3.	Toze, Cynthia L. "Allogeneic haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: outcome in a 20-year cohort." British journal of haematology 158.2 (2012): 174-185.
description	4.	Rodríguez Andrés, A. "Gun control and suicide: The impact of state firearm regulations in the United States, 1995–2004." Health policy 101.1 (2011): 95-103.
description	5.	Plosker, Greg L L. "Bendamustine: a review of its use in the management of indolent non-hodgkin lymphoma." Drugs 68.18 (2008): 2645-60.
description	6.	Kleck, G. "Why do people support gun control?: Alternative explanations of support for handgun bans." Journal of Criminal Justice 37.5 (2009): 496-2504.
description	7.	Boylan, M. "Debate: Gun Control in the United States." Clinical orthopaedics and related research 471.12 (2013): 3934-3936.
description	8.	"Gun Control in the United States: A Comparative Survey of State Firearm Laws.(Brief Article)." Spectrum; The Journal of State Government 73.4 (2000): 16-.
description	9.	Sumner, Steven A., A. "Firearm Death Rates and Association with Level of Firearm Purchase Background Check." American journal of preventive medicine 35.1 (2008): 1-6.
description	10.	Sehn, Laurie H. "A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies." Blood 119.22 (2012): 5118-5125.
description	11.	Rigacci, L. "Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients : A multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL)." Annals of hematology 91.7 (2012): 1013-1022.
description	12.	Plunkett, W. "Inhibition of fludarabine metabolism by arabinosylcytosine during therapy." Cancer Chemotherapy and Pharmacology (1992): 193-9.
description	13.	Zimring, F. "Is Gun Control Likely to Reduce Violent Killings?" The University of Chicago law review 35.4 (1968): 721-737.
description	14.	Agouridis, A P. "New-onset extremely low levels of high-density lipoprotein cholesterol." Journal of clinical lipidology (2012).
description	15.	Robak, T. "Rituximab for chronic lymphocytic leukemia." Expert opinion on biological therapy 12.4 (2012): 503-515.
description	16.	Hillmen, P. "Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial." Journal of clinical oncology 30.14 (2012): 1647-1655.
description	17.	Rodeghiero, F. "Short- and long-term risks of splenectomy for benign haematological disorders: should we revisit the indications?" British journal of haematology 158.1 (2012): 16-29.
description	18.	Law, J. "Busulfan, Fludarabine, and Alemtuzumab as a Reduced Toxicity Regimen for Children with Malignant and non-Malignant Diseases Improves Engraftment and Graft Versus Host Disease without Delaying Immune Reconstitution." Biology of blood and marrow transplantation 18.11 (2012): 1656-1663.
description	19.	Dreger, P. "Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia:long-term clinical and MRD results of the GCLLSG CLL3X trial." Blood 116.14 (2010): 2438-2447.
description	20.	Cheson, Bruce D. "Ofatumumab, a Novel Anti-CD20 Monoclonal Antibody for the Treatment of B-Cell Malignancies." Journal of clinical oncology 28.21 (2010): 3525-3530.